Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
NCT ID NCT07738367
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This phase II trial is testing a procedure called bronchial artery chemoembolization (BACE) combined with systemic anti-cancer drugs in people with advanced non-small cell lung cancer who have no standard treatment options left. BACE delivers chemotherapy directly to the blood vessels feeding the tumor and then blocks them, aiming to increase drug exposure and cut off the tumor's blood supply. The study will see if this combination can control tumor growth in the chest and how safe it is, while also exploring effects on the immune system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bronchial artery chemoembolization (BACE) combined with systemic anti-tumor medications (chemotherapy, immune checkpoint inhibitors, or targeted agents)
- What this could lead to
- If successful, this approach could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies, potentially helping to control tumors in the chest and improve outcomes.
- What could go wrong
- This is a small, early-phase study, so results may not apply to everyone. The combination therapy could cause side effects, and it is not yet known if it will be more effective than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart patch and app aim to boost lung recovery after cancer surgery
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Custom-Made vaccine aims to stop lung cancer recurrence
- Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
- New study aims to tame cholesterol side effect of lung cancer drug
- New pill targets Hard-to-Treat cancers with a specific gene mutation